Humulin R (Insulin Human (Rdna))

Humulin R is used to control blood glucose levels in patients with diabetes. It is appropriate for both type 1 and type 2 diabetes and may be employed as part of a basal‑bolus regimen or in combination with other antidiabetic agents.

• Initiation of insulin therapy in newly diagnosed type 1 diabetes.
• Supplemental insulin for type 2 diabetes when oral agents are insufficient.
• Management of hyperglycemia during illness or stress.
• Adjunctive therapy in diabetic ketoacidosis after initial fluid and electrolyte replacement.
• Adjustments for meals and physical activity in insulin‑treated patients.

• Humulin R contains recombinant human insulin that binds to insulin receptors on cell membranes, activating the intrinsic tyrosine kinase activity. This triggers downstream signaling pathways, including the PI3‑K/Akt cascade, which enhances glucose transporter (GLUT4) translocation to the cell surface, increases peripheral glucose uptake, suppresses hepatic gluconeogenesis, and promotes glycogen synthesis, thereby lowering plasma glucose concentrations.

Humulin R may cause a range of adverse reactions, ranging from mild to severe. Awareness of common and serious events helps clinicians monitor patients effectively.

Common

• Hypoglycemia (low blood glucose)
• Injection‑site pain or erythema
• Lipodystrophy at the injection site
• Weight gain
• Allergic skin reactions such as rash or pruritus

Serious

• Severe hypoglycemia with neuroglycopenic symptoms
• Anaphylactic reaction or angioedema
• Persistent hyperglycemia indicating insulin resistance
• Edema or congestive heart failure exacerbation
• Hypersensitivity leading to urticaria or bronchospasm

When prescribing Humulin R, clinicians should consider patient‑specific factors and monitor for potential complications.

• Assess renal and hepatic function before initiating therapy.
• Adjust dose in patients with fluctuating dietary intake or exercise patterns.
• Use caution in pregnant or breastfeeding women; category B indicates no proven risk.
• Monitor for signs of hypoglycemia, especially in the elderly or those with impaired awareness.
• Educate patients on proper injection technique to reduce lipodystrophy.
• Review concomitant medications that may mask hypoglycemia symptoms.

Humulin R can interact with several drug classes, influencing its efficacy or safety profile.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment, which may precipitate severe hypoglycemia.
• Beta‑blockers that can blunt hypoglycemia warning signs.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Corticosteroids, which may raise glucose levels and require dose escalation.
• Diuretics, especially thiazides, that can affect electrolyte balance and glucose control.
• ACE inhibitors or ARBs, which may potentiate insulin’s glucose‑lowering effect.
• Alcohol, as it can cause unpredictable glucose fluctuations.